Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (239)	10/18/2002 10:17:57 AM
From: Czechsinthemail	Respond to of 362

I'm wondering if this announcement regarding Iloperidone is really an indication that Novartis does not intend to give it back to Titan. They may be playing hardball in their negotiations with Titan or others around selling their interest.

To: Icebrg who wrote (239)	12/11/2002 7:51:18 AM
From: Icebrg	Read Replies (1) \| Respond to of 362

SOUTH SAN FRANCISCO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (ASE: TTP) announced today results of a Phase III, randomized, placebo-controlled study of its monoclonal antibody CeaVac® in patients with metastatic colorectal cancer receiving chemotherapy with 5- flourouracil (5-FU) and leucovorin. Preliminary analysis from the study demonstrated a trend toward overall survival improvement of approximately 2 to 3 months in patients receiving at least 5 doses of CeaVac versus placebo (modified intent-to-treat population) but failed to demonstrate a statistically significant improvement in the primary endpoint of survival in the overall efficacy evaluable population or intent-to-treat population. Message 18324072